← Back to Search

Nicotine Replacement

Nicotine Replacement for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Theodore Brasky, PhD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Head and neck cancer patients planning to undergo surgical resection of their index cancer or exploratory biopsies (tonsil cancer)
Current smokers of combustible cigarettes who smoke >= 4 days/week
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial will test if e-cigarettes are an effective way to help people quit smoking before surgery, in order to reduce the risk of surgery-related complications.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have head and neck cancer and are going to have surgery to remove the main tumor or have a biopsy done (for tonsil cancer).
Select...
You smoke cigarettes at least four days a week.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
7 day point prevalence of tobacco use
Acceptance measured by participation rate
Adherence
+13 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (JUUL)Experimental Treatment3 Interventions
Beginning 1 month before surgery, patients receive a JUUL e-cigarette and a 1 month supply e-liquid pods. After completion of surgery, patients receive another 1 month supply of e-liquid pods.
Group II: Arm II (usual care)Active Control3 Interventions
Patients receive usual care.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotine
FDA approved

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,646 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,607 Previous Clinical Trials
40,913,944 Total Patients Enrolled
Theodore Brasky, PhDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Nicotine Replacement (Nicotine Replacement) Clinical Trial Eligibility Overview. Trial Name: NCT05412875 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Arm I (JUUL), Arm II (usual care)
Non-Small Cell Lung Cancer Clinical Trial 2023: Nicotine Replacement Highlights & Side Effects. Trial Name: NCT05412875 — N/A
Nicotine Replacement (Nicotine Replacement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05412875 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open sign-ups for this research project?

"The information found on clinicaltrials.gov indicates that this trial is not currently enrolling participants, even though it was posted on November 1st 2022 and last modified on August 19th of the same year. Nevertheless, there are 4727 other studies actively recruiting patients at this time."

Answered by AI
~27 spots leftby Mar 2025